Production (Stage)
Tvardi Therapeutics, Inc.
TVRD
$29.09
-$3.79-11.53%
NASDAQ
| 03/31/2025 | 03/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 1.25M | 1.51M | |||
| Total Other Revenue | 1.32M | 623.00K | |||
| Total Revenue | 2.57M | 2.14M | |||
| Cost of Revenue | 319.00K | 22.58M | |||
| Gross Profit | 2.25M | -20.45M | |||
| SG&A Expenses | 4.64M | 6.82M | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.96M | 29.40M | |||
| Operating Income | -2.39M | -27.27M | |||
| Income Before Tax | -4.91M | -30.70M | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -4.91M | -30.70M | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -4.91M | -30.70M | |||
| EBIT | -2.39M | -27.27M | |||
| EBITDA | -- | -27.22M | |||
| EPS Basic | -3.22 | -20.24 | |||
| Normalized Basic EPS | -2.01 | -11.66 | |||
| EPS Diluted | -3.22 | -20.24 | |||
| Normalized Diluted EPS | -2.01 | -11.66 | |||
| Average Basic Shares Outstanding | 1.52M | 1.52M | |||
| Average Diluted Shares Outstanding | 1.52M | 1.52M | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||